Grant: Doctoral Research Award - PA - Bioinformatics and Computational Biology
Direct Payment
$120,000.00
Harnessing whole genome sequencing data for cancer driver discovery and mutational signature characterization.
FY 2024-25
Summary
The past few decades have seen remarkable progress in precision oncology, a cancer treatment paradigm where a patient's unique tumour mutational profile is used to determine the optimal therapeutic regimen for their specific cancer. This approach maximizes treatment efficacy while minimizing normal tissue toxicity. However, as of 2022, approximately 70% of cancer patients remained ineligible for precision oncology therapies because they lacked a therapeutically actionable mutational profile. To increase the number of patients able to benefit from precision oncology, we must identify new clinically predictive genetic subtypes. Due to the vast genetic heterogeneity of cancer, large datasets of matched genomic and clinical information are needed to power such discoveries. The Cancer Genome Atlas (TCGA) is a dataset of over 11,000 DNA-sequenced tumour samples from 33 cancer types. Analysis of this dataset has identified novel driver mutations, defined new cancer subtypes, and produced insights into tumour origin and evolution. However, until now, TCGA consisted primarily of exome sequences, which only include protein-coding regions of the genome. Recently, whole genome sequences became available for ~9500 TCGA samples. This new dataset will enable identification of driver mutations in non-coding genomic regions and characterization of large-scale genomic rearrangements ("structural variants") with unprecedented power. In the proposed project, I aim to use the newly powered TCGA to (1) identify structural variants that drive cancer development and progression and (2) discover mutational patterns that are significantly recurrent across patients. This work will help accelerate discovery of therapeutically actionable mutations and clinically predictive genetic subtypes.
Department
Program
Doctoral Research Award - PA - Bioinformatics and Computational Biology
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
517749
Name
Kowalewski Antonia
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Harnessing whole genome sequencing data for cancer driver discovery and mutational signature characterization.
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA - Bioinformatics and Computational Biology
Keyworddelim
Cancer Genomics; Structural Variation; Whole Genome Analysis
Abstract
The past few decades have seen remarkable progress in precision oncology, a cancer treatment paradigm where a patient's unique tumour mutational profile is used to determine the optimal therapeutic regimen for their specific cancer. This approach maximizes treatment efficacy while minimizing normal tissue toxicity. However, as of 2022, approximately 70% of cancer patients remained ineligible for precision oncology therapies because they lacked a therapeutically actionable mutational profile. To increase the number of patients able to benefit from precision oncology, we must identify new clinically predictive genetic subtypes. Due to the vast genetic heterogeneity of cancer, large datasets of matched genomic and clinical information are needed to power such discoveries. The Cancer Genome Atlas (TCGA) is a dataset of over 11,000 DNA-sequenced tumour samples from 33 cancer types. Analysis of this dataset has identified novel driver mutations, defined new cancer subtypes, and produced insights into tumour origin and evolution. However, until now, TCGA consisted primarily of exome sequences, which only include protein-coding regions of the genome. Recently, whole genome sequences became available for ~9500 TCGA samples. This new dataset will enable identification of driver mutations in non-coding genomic regions and characterization of large-scale genomic rearrangements ("structural variants") with unprecedented power. In the proposed project, I aim to use the newly powered TCGA to (1) identify structural variants that drive cancer development and progression and (2) discover mutational patterns that are significantly recurrent across patients. This work will help accelerate discovery of therapeutically actionable mutations and clinically predictive genetic subtypes.
Competitiondate
202410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kowalewski, Antonia
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~